← boardnext 2027-06
KYMR
Kymera Therapeutics, Inc.distress 5/10 · elevated risk$110.030%today-8% from 52w high
Immunology / Inflammation 1Oncology 1
Lead: atopic dermatitis · target STAT6 · est. market ~$15B (approx, global)
Revenue
$34M
Liquidity
$144M
Runway
0.6 yrs
Shares 1y
+15%
Price & events
+51.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.3%
1D
-3.5%
1W
+12.0%
1M
+26.2%
3M
+57.3%
6M
+137.0%
1Y
+153.1%
2Y
+89.2%
5Y
+78.5%
All
Overview
- Market Cap
- $9.05B
- Volume
- 42.64K
- 52 Week Range
- $37.68 – $119
- Total Shares
- 82.26M
- Float Shares
- 65.16M
- Short %
- 15.92%
- % Held by Insiders
- 2.10%
- % Held by Institutions
- 115.61%
- RVOL
- 0.04x
- Beta
- 1.96
Pipeline stages · 2 programs
KT-621
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
KT-333
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 6 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 2 | KT-621fast track | Atopic Dermatitis | — | active not recruiting |
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 2 | KT-621fast track | Eosinophilic Asthma | — | recruiting |
| 2028-12 Estimated 50% readout ~2029-01-15 | Phase 2 | KT-621fast track | Asthma (Diagnosis) | — | recruiting |
| 2025-11-10 | Phase 1 | KT-621fast track | Atopic Dermatitis | 22 | completed |
| 2025-04-23 | Phase 1 | KT-621fast track | Healthy Participants Study | 118 | completed |
Show all 6 trials · 1 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-03-03 | Phase 1 | KT-333 | Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), T-cell Prolymphocytic Leukemia (T-PLL), Solid Tumors | 56 | completed |
Catalyst news & presentations · 23
- late 2027Guided 55%readoutPhase 2KT-621 · BREADTH Phase 2b asthma trial dataSEC 8-K
- mid-2027Guided 55%readoutPhase 2KT-621 · Data from BROADEN2 Phase 2b trial in moderate to severe ADSEC 8-K
- mid-2027Guided 55%trial initiationsecondaryPhase 3KT-621 · Initiation of Phase 3 trials in ADSEC 8-K
- 2026Guided 40%trial initiationsecondaryPhase 1KT-485 · Phase 1 clinical trial for KT-485/SAR447971SEC 8-K
- second half of 2026Guided 55%readoutPhase 1KT-579 · Data from Phase 1 healthy volunteer trialSEC 8-K
- year-end 2026Guided 70%readoutPhase 2KT-621 · Topline data readout for BROADEN2 trialSEC 8-K
- 2026-08-10earningsEarningsEarnings releaseyahoo
- mid-2026enrollment completesecondaryPhase 2KT-474 · Phase 2b AD completionSEC 8-K
- mid-2026readoutPhase 2KT-474 · Phase 2b study completion in ADSEC 8-K
- 2026-06-25enrollment completesecondaryPhase 2KT-621 · Enrollment completed in BROADEN2 Phase 2b trialSEC 8-K
- first quarter of 2026trial initiationsecondaryPhase 2KT-621 · Phase 2b trial in asthmaSEC 8-K
- first quarter of 2026trial initiationsecondaryPhase 1KT-579 · Initiate Phase 1 healthy volunteer trialSEC 8-K
- early 2026trial initiationsecondaryPhase 1IRF5 · Phase 1 trial start for IRF5 degraderSEC 8-K
- 4Q25readoutPhase 1KT-621 · Data from Phase 1b BroADen trial in moderate to severe AD.SEC 8-K
- fourth quarter of 2025trial initiationsecondaryPhase 2KT-621 · Initiate parallel Phase 2b study in moderate to severe AD.SEC 8-K
- late 2025readoutPhase 1KT-295 · Phase 1 dataSEC 8-K
- June 2025readoutPhase 1KT-621 · Disclose complete Phase 1 SAD/MAD data including STAT6 degradation, safety, and biomarkers.SEC 8-K
- 2Q25trial initiationsecondaryPhase 1KT-621 · Initiate Phase 1b trial in atopic dermatitisSEC 8-K
- 2Q25trial initiationsecondaryPhase 1KT-295 · Initiate Phase 1 trialSEC 8-K
- 2025-06-25trial discontinuedKT-474 · Sanofi will not advance KT-474SEC 8-K
- 2025-06-25partnershipKT-485 · Kymera achieved $20M milestone in Q2 2025 for KT-485 preclinical activities under Sanofi collaborationSEC 8-K
- 2025-06-25partnershipCDK2 degrader · Entered exclusive option and license agreement with Gilead for CDK2 molecular glue degraders; eligible for up to $750M total payments.SEC 8-K
- 2025-05-09trial discontinuedKT-295 · Strategic decision not to advance KT-295 into further clinical development.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $125 (+14% upside) · 21 analysts
- 2026-07-16MizuhoOutperform
- 2026-07-13RBC CapitalOutperform → Sector Perform
- 2026-06-30B of A SecuritiesBuy
- 2026-06-29Truist SecuritiesBuy
- 2026-06-29B. Riley SecuritiesBuy
- 2026-06-26Canaccord GenuityBuy
Competitors — STAT6
- none identified
Recent news
- 2026-07-17Law firm probes Kymera Therapeutics' officers f... - Pluang
- 2026-07-16KYMR Maintained by Mizuho -- Price Target Raised to $140 - GuruFocus
- 2026-07-16SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) - PR Newswire
- 2026-07-16Kymera Therapeutics (KYMR) AGM 2024 Summary - Quartr
- 2026-07-16Kymera Therapeutics (KYMR) Jefferies London Healthcare Conference 2025 Summary - Quartr
- 2026-07-16Kymera Therapeutics (KYMR) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr
- 2026-07-09Is Kymera (KYMR) the Best Performing American Stock in June 2026? - Yahoo Finance
- 2026-07-08Kymera Therapeutics (KYMR) Citi's Biopharma Back to School Conference Summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.